| Year |
Citation |
Score |
| 2024 |
Jordan JT, Shen L, Cooper NJ, Goncalves SV, Trivedi MH, Schatzberg AF, Wu W, Savitz AJ, Etkin A. Baseline Cognition Is Not Associated With Depression Outcomes in Vortioxetine for Major Depressive Disorder: Findings From Placebo-Controlled Trials. The Journal of Clinical Psychiatry. 85. PMID 39240698 DOI: 10.4088/JCP.24m15295 |
0.595 |
|
| 2024 |
DeBattista C, Schatzberg AF. The Black Book of Psychotropic Dosing and Monitoring. Psychopharmacology Bulletin. 54: 8-59. PMID 38993656 |
0.314 |
|
| 2024 |
Solvason HB, Marianayagam NJ, Soltys SG, Schatzberg AF, DeBattista C, Ketter T, Wang P, Chang SD, Spiegel D, Adler JR. Treatment of Refractory Bipolar Depression With Stereotactic Radiosurgery Targeting the Subgenual Cingulate Cortex. Cureus. 16: e57904. PMID 38725772 DOI: 10.7759/cureus.57904 |
0.39 |
|
| 2024 |
Watson KT, Keller J, Spiro CM, Satz IB, Goncalves SV, Pankow H, Kosti I, Lehallier B, Sequeira A, Bunney WE, Rasgon NL, Schatzberg AF. Proteomic profiles of cytokines and chemokines in moderate to severe depression: Implications for comorbidities and biomarker discovery. Brain, Behavior, & Immunity - Health. 36: 100731. PMID 38435722 DOI: 10.1016/j.bbih.2024.100731 |
0.364 |
|
| 2023 |
Lii TR, Smith AE, Flohr JR, Okada RL, Nyongesa CA, Cianfichi LJ, Hack LM, Schatzberg AF, Heifets BD. Randomized trial of ketamine masked by surgical anesthesia in patients with depression. Nature Mental Health. 1: 876-886. PMID 38188539 DOI: 10.1038/s44220-023-00140-x |
0.38 |
|
| 2023 |
Vreijling SR, Chin Fatt CR, Williams LM, Schatzberg AF, Usherwood T, Nemeroff CB, Rush AJ, Uher R, Aitchison KJ, Köhler-Forsberg O, Rietschel M, Trivedi MH, Jha MK, Penninx BWJH, Beekman ATF, et al. Features of immunometabolic depression as predictors of antidepressant treatment outcomes: pooled analysis of four clinical trials. The British Journal of Psychiatry : the Journal of Mental Science. 1-9. PMID 38130122 DOI: 10.1192/bjp.2023.148 |
0.402 |
|
| 2023 |
McIntyre RS, Alsuwaidan M, Baune BT, Berk M, Demyttenaere K, Goldberg JF, Gorwood P, Ho R, Kasper S, Kennedy SH, Ly-Uson J, Mansur RB, McAllister-Williams RH, Murrough JW, Nemeroff CB, ... ... Schatzberg AF, et al. Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions. World Psychiatry : Official Journal of the World Psychiatric Association (Wpa). 22: 394-412. PMID 37713549 DOI: 10.1002/wps.21120 |
0.584 |
|
| 2023 |
Schatzberg AF, Mathew SJ. The why, when, where, how, and so what of so-called rapidly acting antidepressants. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 37460770 DOI: 10.1038/s41386-023-01647-8 |
0.349 |
|
| 2023 |
Hack LM, Tozzi L, Zenteno S, Olmsted AM, Hilton R, Jubeir J, Korgaonkar MS, Schatzberg AF, Yesavage JA, O'Hara R, Williams LM. A Cognitive Biotype of Depression and Symptoms, Behavior Measures, Neural Circuits, and Differential Treatment Outcomes: A Prespecified Secondary Analysis of a Randomized Clinical Trial. Jama Network Open. 6: e2318411. PMID 37318808 DOI: 10.1001/jamanetworkopen.2023.18411 |
0.359 |
|
| 2023 |
Reich J, Schatzberg A. Childhood maladaptive coping mechanisms and the subsequent development of depression. Clinical Psychology & Psychotherapy. PMID 36652398 DOI: 10.1002/cpp.2831 |
0.411 |
|
| 2022 |
Schatzberg AF. An Innovative Approach to Extending the Antidepressant Effects of Intravenous Ketamine in Major Depression. The American Journal of Psychiatry. 179: 890-891. PMID 36453033 DOI: 10.1176/appi.ajp.20220812 |
0.395 |
|
| 2021 |
Sforzini L, Worrell C, Kose M, Anderson IM, Aouizerate B, Arolt V, Bauer M, Baune BT, Blier P, Cleare AJ, Cowen PJ, Dinan TG, Fagiolini A, Ferrier IN, Hegerl U, ... ... Schatzberg AF, et al. A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials. Molecular Psychiatry. PMID 34907394 DOI: 10.1038/s41380-021-01381-x |
0.34 |
|
| 2021 |
Cole EJ, Phillips AL, Bentzley BS, Stimpson KH, Nejad R, Barmak F, Veerapal C, Khan N, Cherian K, Felber E, Brown R, Choi E, King S, Pankow H, Bishop JH, ... ... Schatzberg AF, et al. Stanford Neuromodulation Therapy (SNT): A Double-Blind Randomized Controlled Trial. The American Journal of Psychiatry. appiajp202120101429. PMID 34711062 DOI: 10.1176/appi.ajp.2021.20101429 |
0.777 |
|
| 2021 |
Heifets BD, Bentzley BS, Williams N, Schatzberg AF. Unraveling the opioid actions of S-ketamine and R-ketamine: comment on Bonaventura et al. Molecular Psychiatry. PMID 34006965 DOI: 10.1038/s41380-021-01167-1 |
0.427 |
|
| 2020 |
Fischer AS, Holt-Gosselin B, Fleming SL, Hack LM, Ball TM, Schatzberg AF, Williams LM. Intrinsic reward circuit connectivity profiles underlying symptom and quality of life outcomes following antidepressant medication: a report from the iSPOT-D trial. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 33230268 DOI: 10.1038/s41386-020-00905-3 |
0.687 |
|
| 2020 |
Fischer AS, Tapert SF, Lee Louie D, Schatzberg AF, Singh MK. Cannabis and the Developing Adolescent Brain. Current Treatment Options in Psychiatry. 7: 144-161. PMID 32714742 DOI: 10.1007/S40501-020-00202-2 |
0.636 |
|
| 2020 |
Cole EJ, Stimpson KH, Bentzley BS, Gulser M, Cherian K, Tischler C, Nejad R, Pankow H, Choi E, Aaron H, Espil FM, Pannu J, Xiao X, Duvio D, Solvason HB, ... ... Schatzberg AF, et al. Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression. The American Journal of Psychiatry. appiajp201919070720. PMID 32252538 DOI: 10.1176/Appi.Ajp.2019.19070720 |
0.768 |
|
| 2020 |
Sudheimer K, Duvio D, Shols E, Heinemeyer E, Williams N, O'Hara R, Schatzberg A. The Effects of Cortisol on Subgenual Cingulate Activity in Depression Biological Psychiatry. 87: S449. DOI: 10.1016/J.Biopsych.2020.02.1143 |
0.794 |
|
| 2020 |
Holt-Gosselin B, Fischer A, Fleming S, Hack L, Ball T, Schatzberg A, Williams LM. Functional Connectivity of Reward Circuitry is a Core Mechanistic Biomarker of Treatment Response and Quality of Life in Depression Biological Psychiatry. 87: S396-S397. DOI: 10.1016/J.Biopsych.2020.02.1014 |
0.726 |
|
| 2020 |
Fischer AS, Tapert SF, Louie DL, Schatzberg AF, Singh MK. Cannabis and the Developing Adolescent Brain Current Treatment Options in Psychiatry. 7: 144-161. DOI: 10.1007/s40501-020-00202-2 |
0.61 |
|
| 2019 |
Williams NR, Heifets BD, Bentzley BS, Blasey C, Sudheimer KD, Hawkins J, Lyons DM, Schatzberg AF. Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism. Molecular Psychiatry. PMID 31467392 DOI: 10.1038/S41380-019-0503-4 |
0.748 |
|
| 2019 |
Heifets BD, Williams NR, Bentzley BS, Schatzberg AF. Rigorous Trial Design Is Essential to Understand the Role of Opioid Receptors in Ketamine's Antidepressant Effect. Jama Psychiatry. PMID 31042274 DOI: 10.1001/Jamapsychiatry.2019.0766 |
0.491 |
|
| 2019 |
Schatzberg AF. Scientific Issues Relevant to Improving the Diagnosis, Risk Assessment, and Treatment of Major Depression. The American Journal of Psychiatry. 176: 342-347. PMID 31039643 DOI: 10.1176/appi.ajp.2019.19030273 |
0.333 |
|
| 2019 |
Heifets BD, Williams NR, Blasey C, Sudheimer K, Rodriguez CI, Schatzberg AF. Rigorous Translational Models Are Key to Studying Ketamine's Antidepressant Mechanism: Response to Wang and Kaplin. The American Journal of Psychiatry. 176: 412. PMID 31039633 DOI: 10.1176/Appi.Ajp.2019.19010044R |
0.713 |
|
| 2019 |
Heifets BD, Williams NR, Blasey C, Sudheimer K, Rodriguez CI, Schatzberg AF. Interpreting Ketamine's Opioid Receptor Dependent Effect: Response to Sanacora. The American Journal of Psychiatry. 176: 249-250. PMID 30818991 DOI: 10.1176/Appi.Ajp.2018.18091061R |
0.706 |
|
| 2019 |
Heifets BD, Williams NR, Blasey C, Sudheimer K, Rodriguez CI, Schatzberg AF. Target Population, Dose, and Timing Considerations for Understanding Naltrexone's Subjective Effect: Response to Amiaz. The American Journal of Psychiatry. 176: 251-252. PMID 30818989 DOI: 10.1176/Appi.Ajp.2018.18111231R |
0.692 |
|
| 2019 |
Meyer BM, Rabl U, Huemer J, Bartova L, Kalcher K, Provenzano J, Brandner C, Sezen P, Kasper S, Schatzberg AF, Moser E, Chen G, Pezawas L. Prefrontal networks dynamically related to recovery from major depressive disorder: a longitudinal pharmacological fMRI study. Translational Psychiatry. 9: 64. PMID 30718459 DOI: 10.1038/s41398-019-0395-8 |
0.677 |
|
| 2019 |
Sudheimer K, Duvio D, James D, Heinemeyer E, Pirog S, Williams N, Schatzberg A. F140. The Effects of Cortisol Administration on Emotion, Stress Reactivity, and Brain Activity in Depression Biological Psychiatry. 85: S267. DOI: 10.1016/J.Biopsych.2019.03.677 |
0.756 |
|
| 2019 |
Goldstein A, Tozzi L, Sudheimer K, Schatzberg A, Williams L. T13. Functional Impacts of Acute Stress on Negative Affective Circuit Function in Anxiety and Depression Biological Psychiatry. 85: S134. DOI: 10.1016/J.Biopsych.2019.03.336 |
0.722 |
|
| 2019 |
Williams N, Heifets B, Bentzley B, Blasey C, Sudheimer K, Lyons D, Schatzberg A. O19. Attenuation of Anti-Suicidal Effects of Ketamine by Opioid Receptor Antagonism Biological Psychiatry. 85: S113. DOI: 10.1016/J.Biopsych.2019.03.284 |
0.711 |
|
| 2018 |
Williams NR, Heifets BD, Blasey C, Sudheimer K, Pannu J, Pankow H, Hawkins J, Birnbaum J, Lyons DM, Rodriguez CI, Schatzberg AF. Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism. The American Journal of Psychiatry. appiajp201818020138. PMID 30153752 DOI: 10.1176/Appi.Ajp.2018.18020138 |
0.711 |
|
| 2018 |
Roat-Shumway S, Wroolie TE, Watson K, Schatzberg AF, Rasgon NL. Cognitive effects of mifepristone in overweight, euthymic adults with depressive disorders. Journal of Affective Disorders. 239: 242-246. PMID 30025313 DOI: 10.1016/j.jad.2018.07.014 |
0.303 |
|
| 2018 |
Block TS, Kushner H, Kalin N, Nelson C, Belanoff J, Schatzberg A. Combined Analysis of Mifepristone for Psychotic Depression: Plasma Levels Associated With Clinical Response. Biological Psychiatry. PMID 29523415 DOI: 10.1016/J.Biopsych.2018.01.008 |
0.478 |
|
| 2018 |
Williams NR, Sudheimer KD, Bentzley BS, Pannu J, Stimpson KH, Duvio D, Cherian K, Hawkins J, Scherrer KH, Vyssoki B, DeSouza D, Raj KS, Keller J, Schatzberg AF. High-dose spaced theta-burst TMS as a rapid-acting antidepressant in highly refractory depression. Brain : a Journal of Neurology. PMID 29415152 DOI: 10.1093/Brain/Awx379 |
0.77 |
|
| 2018 |
Davis EG, Keller J, Hallmayer J, Pankow HR, Murphy GM, Gotlib IH, Schatzberg AF. Corticotropin-releasing factor 1 receptor haplotype and cognitive features of major depression. Translational Psychiatry. 8: 5. PMID 29317606 DOI: 10.1038/S41398-017-0051-0 |
0.332 |
|
| 2018 |
Williams N, Sudheimer K, Bentzley B, Pannu J, Stimpson K, Duvio D, Cherian K, Hawkins J, Scherrer K, Vyssoki B, DeSouza D, Raj K, Keller J, Schatzberg A. T162. High-Dose Spaced Theta-Burst Transcranial Magnetic Stimulation as a Rapid-Acting Anti- Depressant in Highly Refractory Depression Biological Psychiatry. 83: S191. DOI: 10.1016/J.Biopsych.2018.02.499 |
0.78 |
|
| 2017 |
Block T, Petrides G, Kushner H, Kalin N, Belanoff J, Schatzberg A. Mifepristone Plasma Level and Glucocorticoid Receptor Antagonism Associated With Response in Patients With Psychotic Depression. Journal of Clinical Psychopharmacology. PMID 28708736 DOI: 10.1097/Jcp.0000000000000744 |
0.479 |
|
| 2017 |
Drysdale AT, Grosenick L, Downar J, Dunlop K, Mansouri F, Meng Y, Fetcho RN, Zebley B, Oathes DJ, Etkin A, Schatzberg AF, Sudheimer K, Keller J, Mayberg HS, Gunning FM, et al. Erratum: Resting-state connectivity biomarkers define neurophysiological subtypes of depression. Nature Medicine. 23: 264. PMID 28170383 DOI: 10.1038/nm0217-264d |
0.799 |
|
| 2017 |
Davis E, Keller J, Hallmayer J, Ryan H, Murphy G, Gotlib I, Schatzberg A. 558. Association of CRHR1 TAT Haplotype with Cognitive Features of Major Depressive Disorder Biological Psychiatry. 81: S225-S226. DOI: 10.1016/J.Biopsych.2017.02.1166 |
0.427 |
|
| 2016 |
Mamdani F, Rollins B, Morgan L, Myers RM, Barchas JD, Schatzberg AF, Watson SJ, Akil H, Potkin SG, Bunney WE, Vawter MP, Sequeira PA. Variable telomere length across post-mortem human brain regions and specific reduction in the hippocampus of major depressive disorder. Translational Psychiatry. 6: e969. PMID 27922633 DOI: 10.1038/tp.2015.164 |
0.31 |
|
| 2016 |
Drysdale AT, Grosenick L, Downar J, Dunlop K, Mansouri F, Meng Y, Fetcho RN, Zebley B, Oathes DJ, Etkin A, Schatzberg AF, Sudheimer K, Keller J, Mayberg HS, Gunning FM, et al. Resting-state connectivity biomarkers define neurophysiological subtypes of depression. Nature Medicine. PMID 27918562 DOI: 10.1038/Nm.4246 |
0.805 |
|
| 2016 |
Goldstein-Piekarski AN, Korgaonkar MS, Green E, Suppes T, Schatzberg AF, Hastie T, Nemeroff CB, Williams LM. Human amygdala engagement moderated by early life stress exposure is a biobehavioral target for predicting recovery on antidepressants. Proceedings of the National Academy of Sciences of the United States of America. 113: 11955-11960. PMID 27791054 DOI: 10.1073/Pnas.1606671113 |
0.327 |
|
| 2016 |
Otte C, Gold SM, Penninx BW, Pariante CM, Etkin A, Fava M, Mohr DC, Schatzberg AF. Major depressive disorder. Nature Reviews. Disease Primers. 2: 16065. PMID 27629598 DOI: 10.1038/nrdp.2016.65 |
0.586 |
|
| 2016 |
Keller J, Gomez R, Williams G, Lembke A, Lazzeroni L, Murphy GM, Schatzberg AF. HPA axis in major depression: cortisol, clinical symptomatology and genetic variation predict cognition. Molecular Psychiatry. PMID 27528460 DOI: 10.1038/mp.2016.120 |
0.303 |
|
| 2016 |
Young CB, Chen T, Nusslock R, Keller J, Schatzberg AF, Menon V. Anhedonia and general distress show dissociable ventromedial prefrontal cortex connectivity in major depressive disorder. Translational Psychiatry. 6: e810. PMID 27187232 DOI: 10.1038/Tp.2016.80 |
0.307 |
|
| 2016 |
Williams LM, Debattista C, Duchemin AM, Schatzberg AF, Nemeroff CB. Childhood trauma predicts antidepressant response in adults with major depression: data from the randomized international study to predict optimized treatment for depression. Translational Psychiatry. 6: e799. PMID 27138798 DOI: 10.1038/Tp.2016.61 |
0.359 |
|
| 2016 |
Williams LM, Goldstein-Piekarski AN, Chowdhry N, Grisanzio KA, Haug NA, Samara Z, Etkin A, O'Hara R, Schatzberg AF, Suppes T, Yesavage J. Developing a clinical translational neuroscience taxonomy for anxiety and mood disorder: protocol for the baseline-follow up Research domain criteria Anxiety and Depression ("RAD") project. Bmc Psychiatry. 16: 68. PMID 26980207 DOI: 10.1186/S12888-016-0771-3 |
0.562 |
|
| 2016 |
Schatzberg A. CRH-R1 allelic variation and depressive and psychotic symptoms in major depression Psychoneuroendocrinology. 71: 8-9. DOI: 10.1016/J.Psyneuen.2016.07.031 |
0.477 |
|
| 2016 |
Schatzberg A. Lifetime achievement award lecture: The HPA axis in psychotic depression Psychoneuroendocrinology. 71: 5. DOI: 10.1016/J.Psyneuen.2016.07.023 |
0.507 |
|
| 2015 |
Williams NR, Schatzberg AF. NMDA antagonist treatment of depression. Current Opinion in Neurobiology. 36: 112-117. PMID 26687375 DOI: 10.1016/J.Conb.2015.11.001 |
0.587 |
|
| 2015 |
Mamdani F, Rollins B, Morgan L, Myers RM, Barchas JD, Schatzberg AF, Watson SJ, Akil H, Potkin SG, Bunney WE, Vawter MP, Sequeira PA. Variable telomere length across post-mortem human brain regions and specific reduction in the hippocampus of major depressive disorder. Translational Psychiatry. 5: e636. PMID 26371764 DOI: 10.1038/Tp.2015.134 |
0.301 |
|
| 2015 |
Schatzberg A. The chicken and egg of anxiety and depression. Epidemiology and Psychiatric Sciences. 24: 227-9. PMID 25997897 DOI: 10.1017/S2045796015000219 |
0.378 |
|
| 2015 |
Schatzberg AF, DeBattista C, Lazzeroni LC, Etkin A, Murphy GM, Williams LM. ABCB1 Genetic Effects on Antidepressant Outcomes: A Report From the iSPOT-D Trial. The American Journal of Psychiatry. appiajp201514050680. PMID 25815420 DOI: 10.1176/Appi.Ajp.2015.14050680 |
0.508 |
|
| 2015 |
Arnow BA, Blasey C, Williams LM, Palmer DM, Rekshan W, Schatzberg AF, Etkin A, Kulkarni J, Luther JF, Rush AJ. Depression Subtypes in Predicting Antidepressant Response: A Report From the iSPOT-D Trial. The American Journal of Psychiatry. appiajp201514020181. PMID 25815419 DOI: 10.1176/Appi.Ajp.2015.14020181 |
0.629 |
|
| 2015 |
Day CV, Gatt JM, Etkin A, DeBattista C, Schatzberg AF, Williams LM. Cognitive and emotional biomarkers of melancholic depression: An iSPOT-D report. Journal of Affective Disorders. 176: 141-50. PMID 25710095 DOI: 10.1016/J.Jad.2015.01.061 |
0.556 |
|
| 2015 |
Saveanu R, Etkin A, Duchemin AM, Goldstein-Piekarski A, Gyurak A, Debattista C, Schatzberg AF, Sood S, Day CV, Palmer DM, Rekshan WR, Gordon E, Rush AJ, Williams LM. The international Study to Predict Optimized Treatment in Depression (iSPOT-D): outcomes from the acute phase of antidepressant treatment. Journal of Psychiatric Research. 61: 1-12. PMID 25586212 DOI: 10.1016/J.Jpsychires.2014.12.018 |
0.777 |
|
| 2015 |
Day CV, John Rush A, Harris AW, Boyce PM, Rekshan W, Etkin A, DeBattista C, Schatzberg AF, Arnow BA, Williams LM. Impairment and distress patterns distinguishing the melancholic depression subtype: an iSPOT-D report. Journal of Affective Disorders. 174: 493-502. PMID 25554994 DOI: 10.1016/J.Jad.2014.10.046 |
0.594 |
|
| 2015 |
Etkin A, Patenaude B, Song YJ, Usherwood T, Rekshan W, Schatzberg AF, Rush AJ, Williams LM. A cognitive-emotional biomarker for predicting remission with antidepressant medications: a report from the iSPOT-D trial. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 40: 1332-42. PMID 25547711 DOI: 10.1038/Npp.2014.333 |
0.576 |
|
| 2015 |
Oathes DJ, Patenaude B, Schatzberg AF, Etkin A. Neurobiological signatures of anxiety and depression in resting-state functional magnetic resonance imaging. Biological Psychiatry. 77: 385-93. PMID 25444162 DOI: 10.1016/J.Biopsych.2014.08.006 |
0.754 |
|
| 2015 |
Bunney BG, Li JZ, Walsh DM, Stein R, Vawter MP, Cartagena P, Barchas JD, Schatzberg AF, Myers RM, Watson SJ, Akil H, Bunney WE. Circadian dysregulation of clock genes: clues to rapid treatments in major depressive disorder. Molecular Psychiatry. 20: 48-55. PMID 25349171 DOI: 10.1038/Mp.2014.138 |
0.346 |
|
| 2015 |
Sudheimer K, Keller J, Gomez R, Tennakoon L, Reiss A, Garrett A, Kenna H, O'Hara R, Schatzberg AF. Decreased hypothalamic functional connectivity with subgenual cortex in psychotic major depression. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 40: 849-60. PMID 25292261 DOI: 10.1038/Npp.2014.259 |
0.745 |
|
| 2015 |
Schatzberg AF. Anna-Monika Award Lecture, DGPPN Kongress, 2013: the role of the hypothalamic-pituitary-adrenal (HPA) axis in the pathogenesis of psychotic major depression. The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry. 16: 2-11. PMID 24933348 DOI: 10.3109/15622975.2014.916414 |
0.378 |
|
| 2015 |
Thompson DG, Kesler SR, Sudheimer K, Mehta KM, Thompson LW, Marquett RM, Holland JM, Reiser R, Rasgon N, Schatzberg A, O'Hara RM. FMRI activation during executive function predicts response to cognitive behavioral therapy in older, depressed adults. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 23: 13-22. PMID 24656506 DOI: 10.1016/J.Jagp.2014.02.001 |
0.725 |
|
| 2015 |
Parry N, Schatzberg AF. Emerging Approaches in the Treatment of Depression Md Conference Express. 15: 15-16. DOI: 10.1177/1559897715593513 |
0.372 |
|
| 2015 |
Staffaroni A, Gomez R, Trettin L, Schatzberg A, Katznelson L, Keller J. A-16The Cognitive Profiles of Cushing's Disease and Psychotic Major Depression Archives of Clinical Neuropsychology. 30: 491.3-492. DOI: 10.1093/arclin/acv047.16 |
0.317 |
|
| 2014 |
Schatzberg AF, Blier P, Culpepper L, Jain R, Papakostas GI, Thase ME. An overview of vortioxetine. The Journal of Clinical Psychiatry. 75: 1411-8. PMID 25551236 DOI: 10.4088/Jcp.14027Ah1 |
0.309 |
|
| 2014 |
Yuen KW, Garner JP, Carson DS, Keller J, Lembke A, Hyde SA, Kenna HA, Tennakoon L, Schatzberg AF, Parker KJ. Plasma oxytocin concentrations are lower in depressed vs. healthy control women and are independent of cortisol. Journal of Psychiatric Research. 51: 30-6. PMID 24405552 DOI: 10.1016/J.Jpsychires.2013.12.012 |
0.353 |
|
| 2014 |
Schatzberg AF, Keller J, Tennakoon L, Lembke A, Williams G, Kraemer FB, Sarginson JE, Lazzeroni LC, Murphy GM. HPA axis genetic variation, cortisol and psychosis in major depression. Molecular Psychiatry. 19: 220-7. PMID 24166410 DOI: 10.1038/mp.2013.129 |
0.402 |
|
| 2014 |
Holland JM, Rozalski V, Thompson KL, Tiongson RJ, Schatzberg AF, O'Hara R, Gallagher-Thompson D. The unique impact of late-life bereavement and prolonged grief on diurnal cortisol. The Journals of Gerontology. Series B, Psychological Sciences and Social Sciences. 69: 4-11. PMID 23740094 DOI: 10.1093/geronb/gbt051 |
0.384 |
|
| 2014 |
Schatzberg AF, Keller J, Tennakoon L, Lembke A, Williams G, Kraemer FB, Sarginson JE, Lazzeroni LC, Murphy GM. Erratum: HPA axis genetic variation, cortisol and psychosis in major depression Molecular Psychiatry. 19: 1151-1151. DOI: 10.1038/MP.2014.57 |
0.341 |
|
| 2013 |
Holland JM, Schatzberg AF, O'Hara R, Marquett RM, Gallagher-Thompson D. Pretreatment cortisol levels predict posttreatment outcomes among older adults with depression in cognitive behavioral therapy. Psychiatry Research. 210: 444-50. PMID 23953171 DOI: 10.1016/J.Psychres.2013.07.033 |
0.36 |
|
| 2013 |
Lee SH, Ripke S, Neale BM, Faraone SV, Purcell SM, Perlis RH, Mowry BJ, Thapar A, Goddard ME, Witte JS, Absher D, Agartz I, Akil H, Amin F, ... ... Schatzberg AF, et al. Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nature Genetics. 45: 984-94. PMID 23933821 DOI: 10.1038/Ng.2711 |
0.408 |
|
| 2013 |
Grieve SM, Korgaonkar MS, Etkin A, Harris A, Koslow SH, Wisniewski S, Schatzberg AF, Nemeroff CB, Gordon E, Williams LM. Brain imaging predictors and the international study to predict optimized treatment for depression: study protocol for a randomized controlled trial. Trials. 14: 224. PMID 23866851 DOI: 10.1186/1745-6215-14-224 |
0.58 |
|
| 2013 |
Medina A, Burke S, Thompson RC, Bunney W, Myers RM, Schatzberg A, Akil H, Watson SJ. Glutamate transporters: a key piece in the glutamate puzzle of major depressive disorder. Journal of Psychiatric Research. 47: 1150-6. PMID 23706640 DOI: 10.1016/J.Jpsychires.2013.04.007 |
0.393 |
|
| 2013 |
Cohen JD, Nichols T, Keller J, Gomez RG, Schatzberg AF, Reiss AL. Insular cortex abnormalities in psychotic major depression: relationship to gender and psychotic symptoms. Neuroscience Research. 75: 331-9. PMID 23471015 DOI: 10.1016/j.neures.2013.02.005 |
0.328 |
|
| 2013 |
Medina A, Seasholtz AF, Sharma V, Burke S, Bunney W, Myers RM, Schatzberg A, Akil H, Watson SJ. Glucocorticoid and mineralocorticoid receptor expression in the human hippocampus in major depressive disorder. Journal of Psychiatric Research. 47: 307-14. PMID 23219281 DOI: 10.1016/J.Jpsychires.2012.11.002 |
0.39 |
|
| 2013 |
Kelley R, Garrett A, Cohen J, Gomez R, Lembke A, Keller J, Reiss AL, Schatzberg A. Altered brain function underlying verbal memory encoding and retrieval in psychotic major depression. Psychiatry Research. 211: 119-26. PMID 23149036 DOI: 10.1016/J.Pscychresns.2012.06.008 |
0.325 |
|
| 2013 |
Lembke A, Gomez R, Tenakoon L, Keller J, Cohen G, Williams GH, Kraemer FB, Schatzberg AF. The mineralocorticoid receptor agonist, fludrocortisone, differentially inhibits pituitary-adrenal activity in humans with psychotic major depression. Psychoneuroendocrinology. 38: 115-21. PMID 22727477 DOI: 10.1016/j.psyneuen.2012.05.006 |
0.376 |
|
| 2012 |
Rush A, Williams L, Koslow S, Wisniewski S, Cooper N, Nemeroff C, Schatzberg A, Gordon E. O-48 - The international study to predict optimized treatment - in depression: rational, design and initial findings European Psychiatry. 27: 1. DOI: 10.1016/S0924-9338(12)74148-2 |
0.343 |
|
| 2011 |
Etkin A, Schatzberg AF. Common abnormalities and disorder-specific compensation during implicit regulation of emotional processing in generalized anxiety and major depressive disorders. The American Journal of Psychiatry. 168: 968-78. PMID 21632648 DOI: 10.1176/Appi.Ajp.2011.10091290 |
0.582 |
|
| 2011 |
Williams LM, Rush AJ, Koslow SH, Wisniewski SR, Cooper NJ, Nemeroff CB, Schatzberg AF, Gordon E. International Study to Predict Optimized Treatment for Depression (iSPOT-D), a randomized clinical trial: rationale and protocol. Trials. 12: 4. PMID 21208417 DOI: 10.7490/F1000Research.1557.1 |
0.393 |
|
| 2011 |
Garrett A, Kelly R, Gomez R, Keller J, Schatzberg AF, Reiss AL. Aberrant brain activation during a working memory task in psychotic major depression. The American Journal of Psychiatry. 168: 173-82. PMID 21078708 DOI: 10.1176/Appi.Ajp.2010.09121718 |
0.386 |
|
| 2010 |
Janicak PG, Nahas Z, Lisanby SH, Solvason HB, Sampson SM, McDonald WM, Marangell LB, Rosenquist P, McCall WV, Kimball J, O'Reardon JP, Loo C, Husain MH, Krystal A, Gilmer W, ... ... Schatzberg AF, et al. Durability of clinical benefit with transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant major depression: assessment of relapse during a 6-month, multisite, open-label study. Brain Stimulation. 3: 187-99. PMID 20965447 DOI: 10.1016/J.Brs.2010.07.003 |
0.315 |
|
| 2010 |
Lindley S, Cacciapaglia H, Noronha D, Carlson E, Schatzberg A. Monitoring mental health treatment acceptance and initial treatment adherence in veterans: veterans of Operations Enduring Freedom and Iraqi Freedom versus other veterans of other eras. Annals of the New York Academy of Sciences. 1208: 104-13. PMID 20955332 DOI: 10.1111/J.1749-6632.2010.05692.X |
0.309 |
|
| 2010 |
Zajecka J, Schatzberg A, Stahl S, Shah A, Caputo A, Post A. Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial. Journal of Clinical Psychopharmacology. 30: 135-44. PMID 20520286 DOI: 10.1097/Jcp.0B013E3181D420A7 |
0.396 |
|
| 2010 |
Parker KJ, Kenna HA, Zeitzer JM, Keller J, Blasey CM, Amico JA, Schatzberg AF. Preliminary evidence that plasma oxytocin levels are elevated in major depression. Psychiatry Research. 178: 359-62. PMID 20494448 DOI: 10.1016/J.Psychres.2009.09.017 |
0.388 |
|
| 2010 |
Rasgon NL, Kenna HA, Williams KE, Powers B, Wroolie T, Schatzberg AF. Rosiglitazone add-on in treatment of depressed patients with insulin resistance: a pilot study. Thescientificworldjournal. 10: 321-8. PMID 20191245 DOI: 10.1100/tsw.2010.32 |
0.376 |
|
| 2010 |
Etkin A, Prater KE, Hoeft F, Menon V, Schatzberg AF. Failure of anterior cingulate activation and connectivity with the amygdala during implicit regulation of emotional processing in generalized anxiety disorder. The American Journal of Psychiatry. 167: 545-54. PMID 20123913 DOI: 10.1176/Appi.Ajp.2009.09070931 |
0.456 |
|
| 2010 |
Reimherr F, Amsterdam J, Dunner D, Adler L, Zhang S, Williams D, Marchant B, Michelson D, Nierenberg A, Schatzberg A, Feldman P. Genetic polymorphisms in the treatment of depression: speculations from an augmentation study using atomoxetine. Psychiatry Research. 175: 67-73. PMID 19969374 DOI: 10.1016/J.Psychres.2009.01.005 |
0.44 |
|
| 2010 |
Sarginson JE, Lazzeroni LC, Ryan HS, Schatzberg AF, Murphy GM. FKBP5 polymorphisms and antidepressant response in geriatric depression. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics. 153: 554-60. PMID 19676097 DOI: 10.1002/ajmg.b.31019 |
0.305 |
|
| 2009 |
Etkin A, Prater KE, Schatzberg AF, Menon V, Greicius MD. Disrupted amygdalar subregion functional connectivity and evidence of a compensatory network in generalized anxiety disorder. Archives of General Psychiatry. 66: 1361-72. PMID 19996041 DOI: 10.1001/Archgenpsychiatry.2009.104 |
0.517 |
|
| 2009 |
Rollins B, Martin MV, Sequeira PA, Moon EA, Morgan LZ, Watson SJ, Schatzberg A, Akil H, Myers RM, Jones EG, Wallace DC, Bunney WE, Vawter MP. Mitochondrial variants in schizophrenia, bipolar disorder, and major depressive disorder. Plos One. 4: e4913. PMID 19290059 DOI: 10.1371/Journal.Pone.0004913 |
0.342 |
|
| 2009 |
Etkin A, Keller K, Menon V, Schatzberg A. Failure of Limbic Regulation by the Medial Prefrontal Cortex in Generalized Anxiety Neuroimage. 47: S49. DOI: 10.1016/S1053-8119(09)70101-6 |
0.482 |
|
| 2008 |
Schatzberg AF. Achieving remission and favorable outcomes in patients with depression/anxiety and substance use disorders. Cns Spectrums. 13: 10-2. PMID 19317018 |
0.331 |
|
| 2008 |
Trivedi MH, Kocsis JH, Thase ME, Morris DW, Wisniewski SR, Leon AC, Gelenberg AJ, Klein DN, Niederehe G, Schatzberg AF, Ninan PT, Keller MB. REVAMP - Research Evaluating the Value of Augmenting Medication with Psychotherapy: rationale and design. Psychopharmacology Bulletin. 41: 5-33. PMID 19015627 |
0.351 |
|
| 2008 |
Keller J, Shen L, Gomez RG, Garrett A, Solvason HB, Reiss A, Schatzberg AF. Hippocampal and amygdalar volumes in psychotic and nonpsychotic unipolar depression. The American Journal of Psychiatry. 165: 872-80. PMID 18450931 DOI: 10.1176/Appi.Ajp.2008.07081257 |
0.409 |
|
| 2008 |
Krystal JH, Carter CS, Geschwind D, Manji HK, March JS, Nestler EJ, Zubieta JK, Charney DS, Goldman D, Gur RE, Lieberman JA, Roy-Byrne P, Rubinow DR, Anderson SA, Barondes S, ... ... Schatzberg AF, et al. It is time to take a stand for medical research and against terrorism targeting medical scientists. Biological Psychiatry. 63: 725-7. PMID 18371494 DOI: 10.1016/J.Biopsych.2008.03.005 |
0.481 |
|
| 2008 |
Kalali A, Vaccarino A, Evans K, Kennedy S, Kobak K, Sills T, Sheehan D, Williams J, Greist J, Schatzberg A. P.2.a.010 The depression inventory development workgroup: results from the second validation study European Neuropsychopharmacology. 18: S298. DOI: 10.1016/S0924-977X(08)70399-7 |
0.462 |
|
| 2008 |
Solvason HB, Schatzberg A. Current Prognosis of Depression Biology of Depression: From Novel Insights to Therapeutic Strategies. 223-251. DOI: 10.1002/9783527619672.ch8 |
0.379 |
|
| 2008 |
Duman R, Polan HJ, Schatzberg A, Kandel ER. Neurobiologic Foundations of Mood Disorders Psychiatry: Third Edition. 1: 339-353. DOI: 10.1002/9780470515167.ch21 |
0.37 |
|
| 2007 |
Montgomery SA, Baldwin DS, Blier P, Fineberg NA, Kasper S, Lader M, Lam RW, Lépine JP, Möller HJ, Nutt DJ, Rouillon F, Schatzberg AF, Thase ME. Which antidepressants have demonstrated superior efficacy? A review of the evidence. International Clinical Psychopharmacology. 22: 323-9. PMID 17917550 DOI: 10.1097/Yic.0B013E3282Eff7E0 |
0.354 |
|
| 2007 |
Kocsis JH, Thase ME, Trivedi MH, Shelton RC, Kornstein SG, Nemeroff CB, Friedman ES, Gelenberg AJ, Dunner DL, Hirschfeld RM, Rothschild AJ, Ferguson JM, Schatzberg AF, Zajecka JM, Pedersen RD, et al. Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT Study. The Journal of Clinical Psychiatry. 68: 1014-23. PMID 17685736 DOI: 10.4088/Jcp.V68N0706 |
0.305 |
|
| 2007 |
Schatzberg AF. Safety and tolerability of antidepressants: weighing the impact on treatment decisions. The Journal of Clinical Psychiatry. 68: 26-34. PMID 17640155 |
0.353 |
|
| 2007 |
Keller J, Schatzberg AF, Maj M. Current issues in the classification of psychotic major depression. Schizophrenia Bulletin. 33: 877-85. PMID 17548842 DOI: 10.1093/schbul/sbm065 |
0.416 |
|
| 2007 |
Michelson D, Adler LA, Amsterdam JD, Dunner DL, Nierenberg AA, Reimherr FW, Schatzberg AF, Kelsey DK, Williams DW. Addition of atomoxetine for depression incompletely responsive to sertraline: a randomized, double-blind, placebo-controlled study. The Journal of Clinical Psychiatry. 68: 582-7. PMID 17474814 |
0.36 |
|
| 2007 |
Greicius MD, Flores BH, Menon V, Glover GH, Solvason HB, Kenna H, Reiss AL, Schatzberg AF. Resting-state functional connectivity in major depression: abnormally increased contributions from subgenual cingulate cortex and thalamus. Biological Psychiatry. 62: 429-37. PMID 17210143 DOI: 10.1016/J.Biopsych.2006.09.020 |
0.349 |
|
| 2007 |
Cunningham M, Schatzberg AF. Agomelatine Demonstrates Broad Efficacy in Depression Md Conference Express. 7: 15-16. DOI: 10.1177/155989770700700208 |
0.401 |
|
| 2007 |
Green AI, Schatzberg AF. Joseph J Schildkraut, 1934–2006 Neuropsychopharmacology. 32: 1855-1856. DOI: 10.1038/Sj.Npp.1301474 |
0.392 |
|
| 2006 |
Schatzberg AF. New paradigm for treating recurrent depression: from symptom control to managing enduring vulnerabilities. Cns Spectrums. 11: 22-7. PMID 17146415 |
0.372 |
|
| 2006 |
Rush AJ, Kraemer HC, Sackeim HA, Fava M, Trivedi MH, Frank E, Ninan PT, Thase ME, Gelenberg AJ, Kupfer DJ, Regier DA, Rosenbaum JF, Ray O, Schatzberg AF. Report by the ACNP Task Force on response and remission in major depressive disorder. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 31: 1841-53. PMID 16794566 DOI: 10.1038/Sj.Npp.1301131 |
0.313 |
|
| 2006 |
Schatzberg A, Roose S. A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 14: 361-70. PMID 16582045 DOI: 10.1097/01.Jgp.0000194645.70869.3B |
0.442 |
|
| 2006 |
Keller J, Flores B, Gomez RG, Solvason HB, Kenna H, Williams GH, Schatzberg AF. Cortisol circadian rhythm alterations in psychotic major depression. Biological Psychiatry. 60: 275-81. PMID 16458262 DOI: 10.1016/j.biopsych.2005.10.014 |
0.411 |
|
| 2006 |
Keller J, Gomez RG, Kenna HA, Poesner J, DeBattista C, Flores B, Schatzberg AF. Detecting psychotic major depression using psychiatric rating scales. Journal of Psychiatric Research. 40: 22-9. PMID 16165160 DOI: 10.1016/j.jpsychires.2005.07.003 |
0.364 |
|
| 2006 |
Flores BH, Kenna H, Keller J, Solvason HB, Schatzberg AF. Clinical and biological effects of mifepristone treatment for psychotic depression. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 31: 628-36. PMID 16160710 DOI: 10.1038/Sj.Npp.1300884 |
0.346 |
|
| 2006 |
Ohayon MM, Schatzberg AF. Fine-tuning our diagnosis and treatment of depression Journal of Psychiatric Research. 40: 281-282. DOI: 10.1016/j.jpsychires.2006.04.005 |
0.379 |
|
| 2005 |
Debattista C, Solomon A, Arnow B, Kendrick E, Tilston J, Schatzberg AF. The efficacy of divalproex sodium in the treatment of agitation associated with major depression. Journal of Clinical Psychopharmacology. 25: 476-9. PMID 16160625 DOI: 10.1097/01.jcp.0000177552.21338.b0 |
0.435 |
|
| 2005 |
Roose SP, Schatzberg AF. The efficacy of antidepressants in the treatment of late-life depression. Journal of Clinical Psychopharmacology. 25: S1-7. PMID 16027554 DOI: 10.1097/01.jcp.0000162807.84570.6b |
0.305 |
|
| 2005 |
Schatzberg AF, Rush AJ, Arnow BA, Banks PL, Blalock JA, Borian FE, Howland R, Klein DN, Kocsis JH, Kornstein SG, Manber R, Markowitz JC, Miller I, Ninan PT, Rothbaum BO, et al. Chronic depression: medication (nefazodone) or psychotherapy (CBASP) is effective when the other is not. Archives of General Psychiatry. 62: 513-20. PMID 15867104 DOI: 10.1001/Archpsyc.62.5.513 |
0.405 |
|
| 2004 |
Schatzberg AF. Employing pharmacologic treatment of bipolar disorder to greatest effect. The Journal of Clinical Psychiatry. 65: 15-20. PMID 15554791 |
0.384 |
|
| 2004 |
Murphy GM, Hollander SB, Rodrigues HE, Kremer C, Schatzberg AF. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Archives of General Psychiatry. 61: 1163-9. PMID 15520364 DOI: 10.1001/archpsyc.61.11.1163 |
0.336 |
|
| 2004 |
Killen JD, Robinson TN, Ammerman S, Hayward C, Rogers J, Samuels D, Schatzberg AF. Major depression among adolescent smokers undergoing treatment for nicotine dependence. Addictive Behaviors. 29: 1517-26. PMID 15451121 DOI: 10.1016/j.addbeh.2004.02.029 |
0.311 |
|
| 2004 |
Rothschild AJ, Williamson DJ, Tohen MF, Schatzberg A, Andersen SW, Van Campen LE, Sanger TM, Tollefson GD. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology. 24: 365-73. PMID 15232326 DOI: 10.1097/01.jcp.0000130557.08996.7a |
0.32 |
|
| 2004 |
Young EA, Altemus M, Lopez JF, Kocsis JH, Schatzberg AF, DeBattista C, Zubieta JK. HPA axis activation in major depression and response to fluoxetine: a pilot study. Psychoneuroendocrinology. 29: 1198-204. PMID 15219644 DOI: 10.1016/j.psyneuen.2004.02.002 |
0.366 |
|
| 2004 |
Posener JA, Charles DeBattista, Veldhuis JD, Province MA, Williams GH, Schatzberg AF. Process irregularity of cortisol and adrenocorticotropin secretion in men with major depressive disorder. Psychoneuroendocrinology. 29: 1129-37. PMID 15219636 DOI: 10.1016/J.Psyneuen.2004.01.004 |
0.351 |
|
| 2004 |
Schatzberg AF. Pharmacologic treatments of major depression: are two mechanisms really better than one? The Journal of Clinical Psychiatry. 65: 3-4. PMID 15046535 |
0.407 |
|
| 2004 |
Fleming SK, Blasey C, Schatzberg AF. Neuropsychological correlates of psychotic features in major depressive disorders: a review and meta-analysis. Journal of Psychiatric Research. 38: 27-35. PMID 14690768 DOI: 10.1016/S0022-3956(03)00100-6 |
0.315 |
|
| 2003 |
Schatzberg AF. Introduction: treating depression and anxiety to remission. The Journal of Clinical Psychiatry. 64: 3-4. PMID 14658983 |
0.401 |
|
| 2003 |
Nemeroff CB, Heim CM, Thase ME, Klein DN, Rush AJ, Schatzberg AF, Ninan PT, McCullough JP, Weiss PM, Dunner DL, Rothbaum BO, Kornstein S, Keitner G, Keller MB. Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma. Proceedings of the National Academy of Sciences of the United States of America. 100: 14293-6. PMID 14615578 DOI: 10.1073/Pnas.2336126100 |
0.409 |
|
| 2003 |
Schatzberg AF. Efficacy and tolerability of duloxetine, a novel dual reuptake inhibitor, in the treatment of major depressive disorder. The Journal of Clinical Psychiatry. 64: 30-7. PMID 14552654 |
0.38 |
|
| 2003 |
Murphy GM, Kremer C, Rodrigues H, Schatzberg AF. The apolipoprotein E epsilon4 allele and antidepressant efficacy in cognitively intact elderly depressed patients. Biological Psychiatry. 54: 665-73. PMID 14512205 DOI: 10.1016/S0006-3223(03)00174-4 |
0.363 |
|
| 2003 |
Mallick R, Chen J, Entsuah AR, Schatzberg AF. Depression-free days as a summary measure of the temporal pattern of response and remission in the treatment of major depression: a comparison of venlafaxine, selective serotonin reuptake inhibitors, and placebo. The Journal of Clinical Psychiatry. 64: 321-30. PMID 12716275 |
0.369 |
|
| 2003 |
Killen JD, Fortmann SP, Schatzberg A, Hayward C, Varady A. Onset of major depression during treatment for nicotine dependence. Addictive Behaviors. 28: 461-70. PMID 12628619 DOI: 10.1016/S0306-4603(01)00266-0 |
0.469 |
|
| 2003 |
Schatzberg AF. New approaches to managing psychotic depression. The Journal of Clinical Psychiatry. 64: 19-23. PMID 12625801 |
0.43 |
|
| 2003 |
Parker KJ, Schatzberg AF, Lyons DM. Neuroendocrine aspects of hypercortisolism in major depression. Hormones and Behavior. 43: 60-6. PMID 12614635 DOI: 10.1016/S0018-506X(02)00016-8 |
0.386 |
|
| 2003 |
DeBattista C, Solvason HB, Poirier J, Kendrick E, Schatzberg AF. A prospective trial of bupropion SR augmentation of partial and non-responders to serotonergic antidepressants. Journal of Clinical Psychopharmacology. 23: 27-30. PMID 12544372 DOI: 10.1097/00004714-200302000-00005 |
0.352 |
|
| 2003 |
Ohayon MM, Schatzberg AF. Using chronic pain to predict depressive morbidity in the general population. Archives of General Psychiatry. 60: 39-47. PMID 12511171 |
0.363 |
|
| 2003 |
Schatzberg AF. Introduction: Recent Developments in Achieving Depression Remission Journal of Clinical Psychiatry. 64: 4. |
0.399 |
|
| 2002 |
McDonald WM, Salzman C, Schatzberg AF. Depression in the elderly. Psychopharmacology Bulletin. 36: 112-22. PMID 12490827 |
0.392 |
|
| 2002 |
Ohayon MM, Schatzberg AF. Prevalence of depressive episodes with psychotic features in the general population. The American Journal of Psychiatry. 159: 1855-61. PMID 12411219 DOI: 10.1176/appi.ajp.159.11.1855 |
0.39 |
|
| 2002 |
Kocsis JH, Schatzberg A, Rush AJ, Klein DN, Howland R, Gniwesch L, Davis SM, Harrison W. Psychosocial outcomes following long-term, double-blind treatment of chronic depression with sertraline vs placebo. Archives of General Psychiatry. 59: 723-8. PMID 12150648 DOI: 10.1001/Archpsyc.59.8.723 |
0.426 |
|
| 2002 |
Thase ME, Rush AJ, Manber R, Kornstein SG, Klein DN, Markowitz JC, Ninan PT, Friedman ES, Dunner DL, Schatzberg AF, Borian FE, Trivedi MH, Keller MB. Differential effects of nefazodone and cognitive behavioral analysis system of psychotherapy on insomnia associated with chronic forms of major depression. The Journal of Clinical Psychiatry. 63: 493-500. PMID 12088160 DOI: 10.4088/Jcp.V63N0605 |
0.362 |
|
| 2002 |
Davidson JRT, Gadde KM, Fairbank JA, Ranga Rama Krishnan K, Califf RM, Binanay C, Parker CB, Pugh N, Hartwell TD, Vitiello B, Ritz L, Severe J, Cole JO, De Battista C, Murali Doraiswamy P, ... ... Schatzberg AF, et al. Effect of Hypericum perforatum (St John's wort) in major depressive disorder: A randomized controlled trial Journal of the American Medical Association. 287: 1807-1814. PMID 11939866 DOI: 10.1001/JAMA.287.14.1807 |
0.327 |
|
| 2002 |
Schatzberg AF, Prather MR, Keller MB, Rush AJ, Laird LK, Wright CW. Clinical use of nefazodone in major depression: a 6-year perspective. The Journal of Clinical Psychiatry. 63: 18-31. PMID 11890561 |
0.357 |
|
| 2002 |
Charney DS, Nemeroff CB, Lewis L, Laden SK, Gorman JM, Laska EM, Borenstein M, Bowden CL, Caplan A, Emslie GJ, Evans DL, Geller B, Grabowski LE, Herson J, Kalin NH, ... ... Schatzberg AF, et al. National Depressive and Manic-Depressive Association consensus statement on the use of placebo in clinical trials of mood disorders. Archives of General Psychiatry. 59: 262-70. PMID 11879164 DOI: 10.1001/Archpsyc.59.3.262 |
0.316 |
|
| 2002 |
Thase ME, Rush AJ, Howland RH, Kornstein SG, Kocsis JH, Gelenberg AJ, Schatzberg AF, Koran LM, Keller MB, Russell JM, Hirschfeld RM, LaVange LM, Klein DN, Fawcett J, Harrison W. Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression. Archives of General Psychiatry. 59: 233-9. PMID 11879161 DOI: 10.1001/Archpsyc.59.3.233 |
0.326 |
|
| 2002 |
Hirschfeld RM, Dunner DL, Keitner G, Klein DN, Koran LM, Kornstein SG, Markowitz JC, Miller I, Nemeroff CB, Ninan PT, Rush AJ, Schatzberg AF, Thase ME, Trivedi MH, Borian FE, et al. Does psychosocial functioning improve independent of depressive symptoms? A comparison of nefazodone, psychotherapy, and their combination. Biological Psychiatry. 51: 123-33. PMID 11822991 DOI: 10.1016/S0006-3223(01)01291-4 |
0.396 |
|
| 2002 |
Schatzberg AF. Major Depression: Causes or Effects? American Journal of Psychiatry. 159: 1077-1079. DOI: 10.1176/APPI.AJP.159.7.1077 |
0.408 |
|
| 2002 |
Schatzberg AF, Kremer C, Rodrigues HE, Murphy GM, Bari M, Vista C, Baumel B, Blake L, Cheren S, DeBattista C, Eisner L, Falk W, Hand S, Hassman H, Kirby L, et al. Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients American Journal of Geriatric Psychiatry. 10: 541-550. DOI: 10.1097/00019442-200209000-00007 |
0.376 |
|
| 2002 |
Fava M, Falk W, Schatzberg A, Kremer C, Murphy G, Rodrigues H. Mirtazapine versus paroxetine in elderly patients with anxious depression European Neuropsychopharmacology. 12: 425-426. DOI: 10.1016/S0924-977X(02)80739-8 |
0.484 |
|
| 2002 |
Mallick R, Schatzberg A. Depression-free days as a flexible measure of response, remission, and elimination of residual symptoms: A pooled analysis of venlafaxine, SSRIs, and placebo European Neuropsychopharmacology. 12: 235. DOI: 10.1016/S0924-977X(02)80285-1 |
0.33 |
|
| 2002 |
Schwartz G, Such P, Schatzberg A. Reboxetine vs venlafaxine in the treatment of severe major depression European Neuropsychopharmacology. 12: 204-205. DOI: 10.1016/S0924-977X(02)80208-5 |
0.404 |
|
| 2002 |
DeBattista C, Rothschild AJ, Schatzberg AF. A dynamic algorithm for the treatment of psychotic major depression Psychiatric Annals. 32: 681-691. |
0.314 |
|
| 2001 |
Posener JA, DeBattista C, Williams GH, Schatzberg AF. Cortisol feedback during the HPA quiescent period in patients with major depression. The American Journal of Psychiatry. 158: 2083-5. PMID 11729034 |
0.342 |
|
| 2001 |
Belanoff JK, Flores BH, Kalezhan M, Sund B, Schatzberg AF. Rapid reversal of psychotic depression using mifepristone. Journal of Clinical Psychopharmacology. 21: 516-21. PMID 11593077 |
0.41 |
|
| 2001 |
Belanoff JK, Kalehzan M, Sund B, Fleming Ficek SK, Schatzberg AF. Cortisol activity and cognitive changes in psychotic major depression. The American Journal of Psychiatry. 158: 1612-6. PMID 11578992 |
0.408 |
|
| 2001 |
Chu JW, Matthias DF, Belanoff J, Schatzberg A, Hoffman AR, Feldman D. Successful long-term treatment of refractory Cushing's disease with high-dose mifepristone (RU 486). The Journal of Clinical Endocrinology and Metabolism. 86: 3568-73. PMID 11502780 DOI: 10.1210/Jcem.86.8.7740 |
0.341 |
|
| 2001 |
Koran LM, Gelenberg AJ, Kornstein SG, Howland RH, Friedman RA, DeBattista C, Klein D, Kocsis JH, Schatzberg AF, Thase ME, Rush AJ, Hirschfeld RM, LaVange LM, Keller MB. Sertraline versus imipramine to prevent relapse in chronic depression. Journal of Affective Disorders. 65: 27-36. PMID 11426506 DOI: 10.1016/S0165-0327(00)00272-X |
0.355 |
|
| 2001 |
Schatzberg A, Debattista C, Murphy G, Kremer C, Rodrigues H. Mirtazapine versus paroxetine in elderly depressed patients European Neuropsychopharmacology. 11: S195. DOI: 10.1016/S0924-977X(01)80152-8 |
0.382 |
|
| 2001 |
Schatzberg A, Belanoff J, Murphy G. Recent research on pharmacogenetics in geriatric depression and mifepristone in delusional depression European Neuropsychopharmacology. 11: S108-S109. DOI: 10.1016/S0924-977X(01)80022-5 |
0.4 |
|
| 2000 |
Montgomery SA, Schatzberg AF, Guelfi JD, Kasper S, Nemeroff C, Swann A, Zajecka J. Pharmacotherapy of depression and mixed states in bipolar disorder. Journal of Affective Disorders. 59: S39-S56. PMID 11121826 DOI: 10.1016/S0165-0327(00)00178-6 |
0.412 |
|
| 2000 |
Kornstein SG, Schatzberg AF, Thase ME, Yonkers KA, McCullough JP, Keitner GI, Gelenberg AJ, Davis SM, Harrison WM, Keller MB. Gender differences in treatment response to sertraline versus imipramine in chronic depression. The American Journal of Psychiatry. 157: 1445-52. PMID 10964861 |
0.375 |
|
| 2000 |
Kornstein SG, Schatzberg AF, Thase ME, Yonkers KA, McCullough JP, Keitner GI, Gelenberg AJ, Ryan CE, Hess AL, Harrison W, Davis SM, Keller MB. Gender differences in chronic major and double depression. Journal of Affective Disorders. 60: 1-11. PMID 10940442 DOI: 10.1016/S0165-0327(99)00158-5 |
0.388 |
|
| 2000 |
Posener JA, DeBattista C, Williams GH, Chmura Kraemer H, Kalehzan BM, Schatzberg AF. 24-Hour monitoring of cortisol and corticotropin secretion in psychotic and nonpsychotic major depression. Archives of General Psychiatry. 57: 755-60. PMID 10920463 |
0.325 |
|
| 2000 |
DeBattista C, Posener JA, Kalehzan BM, Schatzberg AF. Acute antidepressant effects of intravenous hydrocortisone and CRH in depressed patients: a double-blind, placebo-controlled study. The American Journal of Psychiatry. 157: 1334-7. PMID 10910802 |
0.376 |
|
| 2000 |
Schatzberg AF. Clinical efficacy of reboxetine in major depression. The Journal of Clinical Psychiatry. 61: 31-8. PMID 10910015 |
0.381 |
|
| 2000 |
Schatzberg AF, Posener JA, DeBattista C, Kalehzan BM, Rothschild AJ, Shear PK. Neuropsychological deficits in psychotic versus nonpsychotic major depression and no mental illness. The American Journal of Psychiatry. 157: 1095-100. PMID 10873917 DOI: 10.1176/appi.ajp.157.7.1095 |
0.399 |
|
| 2000 |
Green AI, Tohen M, Patel JK, Banov M, DuRand C, Berman I, Chang H, Zarate C, Posener J, Lee H, Dawson R, Richards C, Cole JO, Schatzberg AF. Clozapine in the treatment of refractory psychotic mania. The American Journal of Psychiatry. 157: 982-6. PMID 10831480 DOI: 10.1176/Appi.Ajp.157.6.982 |
0.496 |
|
| 2000 |
Hirschfeld RM, Montgomery SA, Keller MB, Kasper S, Schatzberg AF, Möller HJ, Healy D, Baldwin D, Humble M, Versiani M, Montenegro R, Bourgeois M. Social functioning in depression: a review. The Journal of Clinical Psychiatry. 61: 268-75. PMID 10830147 DOI: 10.4088/Jcp.V61N0405 |
0.321 |
|
| 2000 |
DeBattista C, Solvason HB, Breen JA, Schatzberg AF. Pramipexole augmentation of a selective serotonin reuptake inhibitor in the treatment of depression. Journal of Clinical Psychopharmacology. 20: 274-5. PMID 10770475 DOI: 10.1097/00004714-200004000-00029 |
0.399 |
|
| 2000 |
Schatzberg A, DeBattista C, Posener J. Glucocorticoids & cognition in depression European Neuropsychopharmacology. 10: 180. DOI: 10.1016/S0924-977X(00)80088-7 |
0.338 |
|
| 2000 |
Schatzberg AF, DeBattista C, Kalchzan M, Posener J. HPA axis activity and cognition in major depression Psychoneuroendocrinology. 25: S18. DOI: 10.1016/S0306-4530(00)90094-5 |
0.341 |
|
| 1999 |
Klein DN, Schatzberg AF, McCullough JP, Dowling F, Goodman D, Howland RH, Markowitz JC, Smith C, Thase ME, Rush AJ, LaVange L, Harrison WM, Keller MB. Age of onset in chronic major depression: relation to demographic and clinical variables, family history, and treatment response. Journal of Affective Disorders. 55: 149-57. PMID 10628884 DOI: 10.1016/S0165-0327(99)00020-8 |
0.356 |
|
| 1999 |
Schatzberg AF, DeBattista C. Phenomenology and treatment of agitation. The Journal of Clinical Psychiatry. 60: 17-20. PMID 10418809 |
0.403 |
|
| 1999 |
Klein DN, Schatzberg AF, McCullough JP, Keller MB, Dowling F, Goodman D, Howland RH, Markowitz JC, Smith C, Miceli R, Harrison WM. Early- versus late-onset dythymic disorder: comparison in out-patients with superimposed major depressive episodes. Journal of Affective Disorders. 52: 187-96. PMID 10357032 DOI: 10.1016/S0165-0327(98)00079-2 |
0.31 |
|
| 1999 |
Schatzberg AF. Antidepressant effectiveness in severe depression and melancholia. The Journal of Clinical Psychiatry. 60: 14-21; discussion 22. PMID 10086479 |
0.416 |
|
| 1998 |
Miller IW, Keitner GI, Schatzberg AF, Klein DN, Thase ME, Rush AJ, Markowitz JC, Schlager DS, Kornstein SG, Davis SM, Harrison WM, Keller MB. The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine. The Journal of Clinical Psychiatry. 59: 608-19. PMID 9862607 DOI: 10.4088/Jcp.V59N1108 |
0.394 |
|
| 1998 |
Rush AJ, Koran LM, Keller MB, Markowitz JC, Harrison WM, Miceli RJ, Fawcett JA, Gelenberg AJ, Hirschfeld RM, Klein DN, Kocsis JH, McCullough JP, Schatzberg AF, Thase ME. The treatment of chronic depression, part 1: study design and rationale for evaluating the comparative efficacy of sertraline and imipramine as acute, crossover, continuation, and maintenance phase therapies. The Journal of Clinical Psychiatry. 59: 589-97. PMID 9862605 |
0.317 |
|
| 1998 |
Keller MB, Kocsis JH, Thase ME, Gelenberg AJ, Rush AJ, Koran L, Schatzberg A, Russell J, Hirschfeld R, Klein D, McCullough JP, Fawcett JA, Kornstein S, LaVange L, Harrison W. Maintenance phase efficacy of sertraline for chronic depression: a randomized controlled trial. Jama. 280: 1665-72. PMID 9831997 DOI: 10.1001/Jama.280.19.1665 |
0.44 |
|
| 1998 |
Schatzberg AF, Samson JA, Rothschild AJ, Bond TC, Regier DA. McLean Hospital depression research facility: early-onset phobic disorders and adult-onset major depression. The British Journal of Psychiatry. Supplement. 29-34. PMID 9829014 |
0.41 |
|
| 1998 |
Montgomery SA, Schatzberg AF. Introduction. Reboxetine: a new selective antidepressant for the treatment of depression. The Journal of Clinical Psychiatry. 59: 3. PMID 9818622 |
0.384 |
|
| 1998 |
Rush AJ, Koran LM, Keller MB, Markowitz JC, Harrison WM, Miceli RJ, Fawcett JA, Gelenberg AJ, Hirschfeld RMA, Klein DN, Kocsis JH, McCullough JP, Schatzberg AF, Thase ME. The Treatment of Chronic Depression, Part 1 The Journal of Clinical Psychiatry. 59: 589-597. DOI: 10.4088/Jcp.V59N1106 |
0.333 |
|
| 1997 |
Debattista C, Solvason HB, Belanoff J, Schatzberg AF. Treatment of psychotic depression. The American Journal of Psychiatry. 154: 1625-6. PMID 9356580 |
0.414 |
|
| 1997 |
Kocsis J, Schatzberg A, Rush A, Korstein S, Klein D, Hirschfeld R. Maintenance therapy of chronic depression: A placebo-controlled trial of sertraline Biological Psychiatry. 42: 240S. DOI: 10.1016/S0006-3223(97)87896-1 |
0.314 |
|
| 1997 |
Thase M, Keller M, Gelenberg A, Hirschfeld R, Schatzberg A. Double-blind crossover antidepressant study: Sertraline vs. imipramine Biological Psychiatry. 42: 230S. DOI: 10.1016/S0006-3223(97)87842-0 |
0.37 |
|
| 1996 |
Schatzberg AF. Treatment of severe depression with the selective serotonin reuptake inhibitors. Depression and Anxiety. 4: 182-9. PMID 9166650 DOI: 10.1002/(SICI)1520-6394(1996)4:4<182::AID-DA4>3.0.CO;2-H |
0.343 |
|
| 1995 |
Kornstein SG, Schatzberg AF, Yonkers KA, Thase ME, Keitner GI, Ryan CE, Schlager D. Gender differences in presentation of chronic major depression. Psychopharmacology Bulletin. 31: 711-8. PMID 8851644 |
0.352 |
|
| 1995 |
Salzman C, Wolfson AN, Schatzberg A, Looper J, Henke R, Albanese M, Schwartz J, Miyawaki E. Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. Journal of Clinical Psychopharmacology. 15: 23-9. PMID 7714224 DOI: 10.1097/00004714-199502000-00005 |
0.402 |
|
| 1995 |
Keller MB, Harrison W, Fawcett JA, Gelenberg A, Hirschfeld RM, Klein D, Kocsis JH, McCullough JP, Rush AJ, Schatzberg A. Treatment of chronic depression with sertraline or imipramine: preliminary blinded response rates and high rates of undertreatment in the community. Psychopharmacology Bulletin. 31: 205-12. PMID 7491369 |
0.408 |
|
| 1995 |
Schatzberg AF, Posener JA, Rothschild AJ. The Role of Dopamine in Psychotic Depression Clinical Neuropharmacology. 18: S66-S73. DOI: 10.1097/00002826-199501001-00009 |
0.325 |
|
| 1994 |
Hirschfeld RM, Schatzberg AF. Long-term management of depression. The American Journal of Medicine. 97: 33S-38S. PMID 7992825 |
0.369 |
|
| 1994 |
Debattista C, Schatzberg AF. An Algorithm for the Treatment of Major Depression and its Subtypes Psychiatric Annals. 24: 341-347. DOI: 10.3928/0048-5713-19940701-08 |
0.337 |
|
| 1993 |
Green AI, Alam MY, Sobieraj JT, Pappalardo KM, Waternaux C, Salzman C, Schatzberg AF, Schildkraut JJ. Clozapine response and plasma catecholamines and their metabolites. Psychiatry Research. 46: 139-49. PMID 8483973 DOI: 10.1016/0165-1781(93)90016-A |
0.452 |
|
| 1993 |
Bowden CL, Schatzberg AF, Rosenbaum A, Contreras SA, Samson JA, Dessain E, Sayler M. Fluoxetine and desipramine in major depressive disorder. Journal of Clinical Psychopharmacology. 13: 305-11. PMID 8227488 |
0.38 |
|
| 1993 |
Rothschild AJ, Samson JA, Bond TC, Luciana MM, Schildkraut JJ, Schatzberg AF. Hypothalamic-pituitary-adrenal axis activity and 1-year outcome in depression. Biological Psychiatry. 34: 392-400. PMID 8218607 DOI: 10.1016/0006-3223(93)90184-F |
0.353 |
|
| 1992 |
Schatzberg AF, Rothschild AJ. Psychotic (delusional) major depression: should it be included as a distinct syndrome in DSM-IV? The American Journal of Psychiatry. 149: 733-45. PMID 1590491 |
0.436 |
|
| 1992 |
Rothschild AJ, Schatzberg AF. Theoretical basis for response to steroid suppression in major depression. Journal of Clinical Psychopharmacology. 12: 142-4. PMID 1573041 |
0.397 |
|
| 1992 |
Schildkraut JJ, Schatzberg AF, Samson JA, Rosenbaum A, Bowden CL. Norepinephrine output and metabolism in depressed patients during antidepressant treatments. Clinical Neuropharmacology. 15: 323A-324A. PMID 1498855 |
0.363 |
|
| 1992 |
Schatzberg AF. Recent developments in the acute somatic treatment of major depression. The Journal of Clinical Psychiatry. 53: 20-5. PMID 1347770 |
0.383 |
|
| 1992 |
Schatzberg AF, Bowden CL, Rosenbaum AH, Samson JA, Dessain E, Schildkraut JJ. EFFECTS OF FLUOXETINE AND DESIPRAMINE ON URINARY CATECHOLAMINE AND METABOLITE EXCRETION IN MAJOR DEPRESSION Clinical Neuropharmacology. 15: 415B. DOI: 10.1097/00002826-199202001-00807 |
0.389 |
|
| 1992 |
bowden c, schatzberg a, rosenbaum a, contreras s, schildkraut j, dessain e. Effects Of Fluoxetine & Desipramine On Platelet Imipramine Binding In Major Depression Clinical Neuropharmacology. 15. DOI: 10.1097/00002826-199202001-00637 |
0.428 |
|
| 1991 |
Mooney JJ, Schatzberg AF, Cole JO, Samson JA, Waternaux C, Gerson B, Pappalardo KM, Schildkraut JJ. Urinary 3-methoxy-4-hydroxyphenylglycol and the depression-type score as predictors of differential responses to antidepressants. Journal of Clinical Psychopharmacology. 11: 339-43. PMID 1770151 |
0.328 |
|
| 1990 |
Schatzberg AF, Samson JA, Rothschild AJ, Luciana MM, Bruno RF, Bond TC. Depression secondary to anxiety: findings from the McLean Hospital Depression Research Facility. The Psychiatric Clinics of North America. 13: 633-49. PMID 2281010 DOI: 10.1016/S0193-953X(18)30340-X |
0.406 |
|
| 1989 |
Rothschild AJ, Benes F, Hebben N, Woods B, Luciana M, Bakanas E, Samson JA, Schatzberg AF. Relationships between brain CT scan findings and cortisol in psychotic and nonpsychotic depressed patients. Biological Psychiatry. 26: 565-75. PMID 2790096 DOI: 10.1016/0006-3223(89)90081-4 |
0.344 |
|
| 1989 |
Schatzberg AF, Samson JA, Bloomingdale KL, Orsulak PJ, Gerson B, Kizuka PP, Cole JO, Schildkraut JJ. Toward a biochemical classification of depressive disorders. X. Urinary catecholamines, their metabolites, and D-type scores in subgroups of depressive disorders. Archives of General Psychiatry. 46: 260-8. PMID 2783211 DOI: 10.1001/Archpsyc.1989.01810030066009 |
0.34 |
|
| 1988 |
Schatzberg AF, Rothschild AJ. The roles of glucocorticoid and dopaminergic systems in delusional (psychotic) depression. Annals of the New York Academy of Sciences. 537: 462-71. PMID 3059936 |
0.354 |
|
| 1987 |
Schatzberg AF, Rothschild AJ, Langlais PJ, Lerbinger JE, Schildkraut JJ, Cole JO. Psychotic and nonpsychotic depressions: II. Platelet MAO activity, plasma catecholamines, cortisol, and specific symptoms. Psychiatry Research. 20: 155-64. PMID 3575560 DOI: 10.1016/0165-1781(87)90007-2 |
0.309 |
|
| 1987 |
Schatzberg AF, Dessain E, O'Neil P, Katz DL, Cole JO. Recent studies on selective serotonergic antidepressants: trazodone, fluoxetine, and fluvoxamine. Journal of Clinical Psychopharmacology. 7: 44S-49S. PMID 3123528 DOI: 10.1097/00004714-198712001-00005 |
0.377 |
|
| 1987 |
Rothschild AJ, Schatzberg AF, Langlais PJ, Lerbinger JE, Miller MM, Cole JO. Psychotic and nonpsychotic depressions: I. Comparison of plasma catecholamines and cortisol measures. Psychiatry Research. 20: 143-53. PMID 2883694 |
0.353 |
|
| 1986 |
Bond TC, Rothschild AJ, Lerbinger J, Schatzberg AF. Delusional depression, family history, and DST response: a pilot study. Biological Psychiatry. 21: 1239-46. PMID 3756274 DOI: 10.1016/0006-3223(86)90306-9 |
0.357 |
|
| 1985 |
Samson JA, Gudeman JE, Schatzberg AF, Kizuka PP, Orsulak PJ, Cole JO, Schildkraut JJ. Toward a biochemical classification of depressive disorders--VIII. Platelet monoamine oxidase activity in subtypes of depressions. Journal of Psychiatric Research. 19: 547-55. PMID 4078757 DOI: 10.1016/0022-3956(85)90072-X |
0.391 |
|
| 1985 |
Schatzberg AF, Rothschild AJ, Langlais PJ, Bird ED, Cole JO. A corticosteroid/dopamine hypothesis for psychotic depression and related states. Journal of Psychiatric Research. 19: 57-64. PMID 2859366 |
0.316 |
|
| 1985 |
Mooney JJ, Cole JO, Schatzberg AF, Gerson B, Schildkraut JJ. Pretreatment urinary MHPG levels as predictors of antidepressant responses to alprazolam. The American Journal of Psychiatry. 142: 366-7. PMID 2857533 |
0.389 |
|
| 1984 |
Schatzberg AF, Rothschild AJ, Bond TC, Cole JO. The DST in psychotic depression: diagnostic and pathophysiologic implications. Psychopharmacology Bulletin. 20: 362-4. PMID 6473631 |
0.413 |
|
| 1983 |
Schatzberg AF, Rothschild AJ, Stahl JB, Bond TC, Rosenbaum AH, Lofgren SB, MacLaughlin RA, Sullivan MA, Cole JO. The dexamethasone suppression test: identification of subtypes of depression. The American Journal of Psychiatry. 140: 88-91. PMID 6847992 |
0.404 |
|
| 1983 |
Rosenbaum AH, Maruta T, Schatzberg AF, Orsulak PJ, Jiang NS, Cole JO, Schildkraut JJ. Toward a biochemical classification of depressive disorders, VII: urinary free cortisol and urinary MHPG in depressions. The American Journal of Psychiatry. 140: 314-8. PMID 6829802 |
0.343 |
|
| 1983 |
Schatzberg AF, Cole JO. Benzodiazepines in the treatment of depressive, borderline personality, and schizophrenic disorders. British Journal of Clinical Pharmacology. 17S-22S. PMID 6133529 DOI: 10.1111/J.1365-2125.1981.Tb01834.X |
0.488 |
|
| 1982 |
Rothschild AJ, Schatzberg AF, Rosenbaum AH, Stahl JB, Cole JO. The dexamethasone suppression test as a discriminator among subtypes of psychotic patients. The British Journal of Psychiatry : the Journal of Mental Science. 141: 471-4. PMID 7150883 |
0.308 |
|
| 1982 |
Gudeman JE, Schatzberg AF, Samson JA, Orsulak PJ, Cole JO, Schildkraut JJ. Toward a biochemical classification of depressive disorders, VI: Platelet MAO activity and clinical symptoms in depressed patients. The American Journal of Psychiatry. 139: 630-3. PMID 7072851 |
0.35 |
|
| 1982 |
Schatzberg AF, Orsulak PJ, Rosenbaum AH, Maruta T, Kruger ER, Cole JO, Schildkraut JJ. Toward a biochemical classification of depressive disorders, V: Heterogeneity of unipolar depressions. The American Journal of Psychiatry. 139: 471-5. PMID 7065292 |
0.404 |
|
| 1981 |
COLE JO, SCHATZBERG AF, SNIFFIN C, ZOLNER J, COLE JP. Trazodone in Treatment-Resistant Depression: An Open Study Journal of Clinical Psychopharmacology. 1: 49S-54S. DOI: 10.1097/00004714-198111001-00010 |
0.362 |
|
| 1981 |
Schatzberg AF, Rosenbaum AH, Orsulak PJ, Rohde WA, Maruta T, Kruger ER, Cole JO, Schildkraut JJ. Toward a biochemical classification of depressive disorders - III: Pretreatment urinary MHPG levels as predictors of response to treatment with maprotiline Psychopharmacology. 75: 34-38. DOI: 10.1007/BF00433498 |
0.359 |
|
| 1978 |
Schildkraut JJ, Orsulak PJ, LaBrie RA, Schatzberg AF, Gudeman JE, Cole JO, Rohde WA. Toward a biochemical classification of depressive disorders. II. Application of multivariate discriminant function analysis to data on urinary catecholamines and metabolites. Archives of General Psychiatry. 35: 1436-9. PMID 727879 DOI: 10.1001/Archpsyc.1978.01770360040004 |
0.399 |
|
| 1978 |
Schildkraut JJ, Orsulak PJ, Schatzberg AF, Gudeman JE, Cole JO, Rohde WA, LaBrie RA. Toward a biochemical classification of depressive disorders. I. Differences in urinary excretion of MHPG and other catecholamine metabolites in clinically defined subtypes of depressions. Archives of General Psychiatry. 35: 1427-33. PMID 727878 DOI: 10.1001/Archpsyc.1978.01770360031003 |
0.424 |
|
| 1978 |
Schatzberg AF, Cole JO. Benzodiazepines in depressive disorders. Archives of General Psychiatry. 35: 1359-65. PMID 30428 DOI: 10.1001/ARCHPSYC.1978.01770350085008 |
0.444 |
|
| Show low-probability matches. |